Avita Medical (RCEL) Stock Forecast & Price Target

Compare

399 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RCEL Analyst Ratings

Moderate Buy

3 Buy

1 Hold

1 Sell

Based on 5 analysts giving stock ratings to

Avita

Medical

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RCEL Stock 12 Month Forecast

Average Price Target

$8.70

▲(54.53% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Avita Medical in the last 3 months. The average price target is $8.70 with a high forecast of $19.00 and a low forecast of $3.00. The average price target represents a 54.53% change from the last price of $5.63.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","11":"$11","20":"$20","6.5":"$6.5","15.5":"$15.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,6.5,11,15.5,20],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.16,6.224615384615385,7.28923076923077,8.353846153846153,9.418461538461539,10.483076923076922,11.547692307692307,12.612307692307692,13.676923076923076,14.741538461538461,15.806153846153846,16.87076923076923,17.935384615384613,{"y":19,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.16,5.432307692307693,5.704615384615384,5.976923076923077,6.249230769230769,6.521538461538461,6.793846153846154,7.066153846153846,7.338461538461538,7.610769230769231,7.883076923076922,8.155384615384616,8.427692307692308,{"y":8.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.16,4.993846153846154,4.827692307692308,4.661538461538462,4.495384615384616,4.32923076923077,4.163076923076924,3.996923076923077,3.830769230769231,3.664615384615385,3.4984615384615387,3.332307692307692,3.166153846153846,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.54,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.55,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.65,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.72,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.72,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.1,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.1,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.34,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.04,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$19.00

Average Price Target$8.70

Lowest Price Target$3.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Lila Implantra

TR | OpenAI - 4o

$5.5

Hold

-2.31%

Downside

Reiterated

08/14/25

AI Generated ArticleAI Generated Article

Frank Takkinen

Lake Street

$14→$8

Buy

42.10%

Upside

Reiterated

08/13/25

Avita Medical assumed with a Buy at Lake StreetAvita Medical assumed with a Buy at Lake Street

Josh Jennings

TD Cowen

$12.5→$8

Buy

42.10%

Upside

Reiterated

08/08/25

TD Cowen Remains a Buy on Avita Medical (RCEL)

Ryan Zimmerman

BTIG

Sell

-46.71%

Downside

Downgraded

08/08/25

Avita Medical downgraded to Sell from Neutral at BTIGAvita Medical downgraded to Sell from Neutral at BTIG

Ross Osborn

Cantor Fitzgerald

$19

Buy

237.48%

Upside

Reiterated

06/09/25

Cantor Fitzgerald Sticks to Their Buy Rating for Avita Medical (RCEL)

Jason Kolbert

D. Boral Capital

$25→$22

Buy

290.76%

Upside

Reiterated

02/20/25

Avita Medical price target lowered to $22 from $25 at D. Boral CapitalAvita Medical price target lowered to $22 from $25 at D. Boral Capital

Matthew O'Brien

Piper Sandler

$12→$11

Hold

95.38%

Upside

Reiterated

02/14/25

Piper Sandler Remains a Hold on Avita Medical (RCEL)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Lila Implantra

TR | OpenAI - 4o

$5.5

Hold

-2.31%

Downside

Reiterated

08/14/25

AI Generated ArticleAI Generated Article

Frank Takkinen

Lake Street

$14→$8

Buy

42.10%

Upside

Reiterated

08/13/25

Avita Medical assumed with a Buy at Lake StreetAvita Medical assumed with a Buy at Lake Street

Josh Jennings

TD Cowen

$12.5→$8

Buy

42.10%

Upside

Reiterated

08/08/25

TD Cowen Remains a Buy on Avita Medical (RCEL)

Ryan Zimmerman

BTIG

Sell

-46.71%

Downside

Downgraded

08/08/25

Avita Medical downgraded to Sell from Neutral at BTIGAvita Medical downgraded to Sell from Neutral at BTIG

Ross Osborn

Cantor Fitzgerald

$19

Buy

237.48%

Upside

Reiterated

06/09/25

Cantor Fitzgerald Sticks to Their Buy Rating for Avita Medical (RCEL)

Jason Kolbert

D. Boral Capital

$25→$22

Buy

290.76%

Upside

Reiterated

02/20/25

Avita Medical price target lowered to $22 from $25 at D. Boral CapitalAvita Medical price target lowered to $22 from $25 at D. Boral Capital

Matthew O'Brien

Piper Sandler

$12→$11

Hold

95.38%

Upside

Reiterated

02/14/25

Piper Sandler Remains a Hold on Avita Medical (RCEL)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Avita Medical

1 Month

xxx

Success Rate

9/21 ratings generated profit

Average Return

+1.73%

downgraded a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 42.86% of your transactions generating a profit, with an average return of +1.73% per trade.

3 Months

xxx

Success Rate

12/21 ratings generated profit

Average Return

+6.66%

downgraded a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +6.66% per trade.

1 Year

Ryan ZimmermanBTIG

Success Rate

9/21 ratings generated profit

Average Return

+5.50%

downgraded a sell rating 9 days ago

Copying Ryan Zimmerman's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of +5.50% per trade.

2 Years

xxx

Success Rate

10/21 ratings generated profit

Average Return

+2.80%

downgraded a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 47.62% of your transactions generating a profit, with an average return of +2.80% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RCEL Analyst Recommendation Trends

Rating

Feb 25

Mar 25

May 25

Jun 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RCEL has received 8 Buy Ratings, 1 Hold Ratings, and 1 Sell Ratings. RCEL average Analyst price target in the past 3 months is 8.70.

Each month's total comprises the sum of three months' worth of ratings.

RCEL Financial Forecast

RCEL Earnings Forecast

Next quarter’s earnings estimate for RCEL is -$0.29 with a range of -$0.38 to -$0.11. The previous quarter’s EPS was -$0.38. RCEL beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.19% of the time in the same period. In the last calendar year RCEL has Preformed in-line its overall industry.

RCEL Sales Forecast

Next quarter’s sales forecast for RCEL is $19.24M with a range of $18.60M to $21.00M. The previous quarter’s sales results were $18.42M. RCEL beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.39% of the time in the same period. In the last calendar year RCEL has Preformed in-line its overall industry.

RCEL Stock Forecast FAQ

What is RCEL’s average 12-month price target, according to analysts?

Based on analyst ratings, Avita Medical’s 12-month average price target is 8.70.

What is RCEL’s upside potential, based on the analysts’ average price target?

Avita Medical has 54.53% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RCEL a Buy, Sell or Hold?

Avita Medical has a consensus rating of Moderate Buy which is based on 3 buy ratings, 1 hold ratings and 1 sell ratings.

What is Avita Medical’s price target?

The average price target for Avita Medical is 8.70. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $19.00 ,the lowest forecast is $3.00. The average price target represents 54.53% Increase from the current price of $5.63.

What do analysts say about Avita Medical?

Avita Medical’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of RCEL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Avita Medical (RCEL) Stock Forecast & Price Target

RCEL Analyst Ratings

RCEL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Avita Medical

RCEL Analyst Recommendation Trends

RCEL Financial Forecast

RCEL Earnings Forecast

RCEL Sales Forecast

RCEL Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts